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This case report describes a complex trauma patient who developed hyperkalemia secondary to 
heparin. Heparin is a commonly used drug in trauma patients. Physicians need to be aware of this 








Deep venous thrombosis (DVT) is a serious potential complication of trauma. In his classic 
article, Geerts et al identified risk factors for developing DVT in trauma patients, with head 
injuries, spinal cord injuries, and lower extremity fractures at the highest risk.1 Prophylactic 
anticoagulation is recommended in these high-risk patients.2-4 We present a high-risk trauma 




A 47-year-old male was an unrestrained passenger involved in a rollover motor vehicle crash. 
The patient was confused at the scene. Emergency medical service transported the patient to 
Cabell Huntington Hospital. The patient arrived hemodynamically stable (blood pressure 
124/106 mm Hg, pulse 76 beats/minute, respiratory rate 20 respirations/minute, oral temperature 
98.1ºF). The patient was not moving his legs, and he underwent multiple computed tomography 
(CT) scans – head, cervical spine, chest, abdominal, and pelvis with reconstructions of the 
thoracic and lumbar spines. No intracranial injury was identified. The CT of the cervical spine 
revealed bilateral jumped facets at C7-T1 with high-grade spinal stenosis with possible crush 
injury to the spinal cord. A fracture of the sternum was seen on the patient’s chest CT along with 
a posterior mediastinal paraspinous hematoma which extended from T1 to T4. The CT of the 
abdomen/pelvis revealed an acetabular fracture as well as an L5 superior endplate fracture 
without compromise of the spinal canal. The kidneys were normal. Admission labs were 
unremarkable including a potassium level of 3.8 mEq/L. The patient’s past medical history 
included hypertension and diabetes. The patient also reportedly had a stroke several years earlier 
and was taking aspirin prophylactically. The patient was a one pack per day smoker. 
 
While in the emergency room, the patient developed neurogenic shock but responded 
appropriately to resuscitative efforts which included fluid and norepinephrine. He was admitted 
to the intensive care unit. Orthopedics and neurosurgery were consulted. The patient was placed 
in traction via a distal femur pin for his acetabular fracture. The patient was taken to the 
operating room by neurosurgery on post-injury day 1 where he underwent reduction of his C7/T1 
jumped facets with internal fixation. The patient remained intubated postoperatively.  
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The patient spiked a fever on post-injury day 2. He was pan-cultured which revealed community-
acquired pneumonia with Haemophilus influenza. He was treated with broad-spectrum 
antibiotics and subsequent, directed de-escalation based on susceptibility results. However, the 
patient developed septic shock in spite of adequate antibiotic coverage for H. influenza. He 
stabilized within hours after receiving a combination of fluids and pressors. 
 
Also, on post-injury day 2, the patient’s creatinine was within normal limits (0.98 mg/dL) and he 
was started on prophylactic enoxaparin as per the hospital protocol for patients with spinal cord 
injuries. However, his renal function deteriorated, and his creatinine was elevated to 2.32 mg/dL 
on post-injury day 6. In spite of adequate blood pressure and no evidence of hypovolemia, the 
patient’s creatinine continued to climb to 2.60 mg/dl. Nephrology was consulted and a 
retroperitoneal ultrasound was performed, which was normal. The patient was switched from 
D51/2 NS to D5W infused at 75 mL/hr. The cause of his worsening renal function was thought 
to be multifactorial relative to shock and CT contrast dye. The patient was switched from 
enoxaparin to 5,000 units of subcutaneous heparin three times daily.  
 
Simultaneous to the patient’s decline in renal function, the patient’s respiratory status continued 
to deteriorate. Using a lung-protective strategy to manage the ventilator, the patient was placed 
on airway pressure release ventilation (APRV). However, the patient developed progressive 
hypoxia in spite of being on mechanical ventilation. The patient was pan-cultured for suspected 
sepsis; all cultures were negative. The patient became more hypoxic with tachycardia and 
hypotension. The patient was not responsive to fluid challenges and norepinephrine was started 
to support the patient’s blood pressure. Our goal was to maintain a mean arterial pressure greater 
than 65 mmHg. The patient was started on broad-spectrum antibiotics of piperacillin-tazobactam 
and linezolid. 
 
On post-injury day 10, a noninvasive cardiac monitor was placed on the patient and an 
echocardiogram was obtained which revealed an ejection fraction of 60% with no wall motion 
abnormalities. However, the patient’s inferior vena cava was dilated with poor inspiratory 
collapse. The non-invasive cardiac monitor revealed a low cardiac index and a modestly high 
systemic vascular resistance which suggested that the patient’s hypotension was probably 
secondary to cardiac dysfunction. The patient became persistently tachycardiac while on 
norepinephrine. He was switched to dobutamine which resolved his tachycardia and increased 
his mean arterial pressure to greater than 65 mmHg.  
 
The patient’s respiratory status began to improve, and the patient’s dobutamine was weaned off. 
The patient was fluid overloaded. Furosemide was given and the patient voided more than six 
liters of fluid over two days. The patient’s potassium climbed to 6 mEq/L in spite of conservative 
measures such as removing potassium from IV fluids, so insulin and albuterol were given. 
Nephrology suggested that the patient’s subcutaneous heparin be stopped. The heparin was 
discontinued and fondaparinux was started at 2.5 mg subcutaneously (Figure 1). Over the next 
ten days, the patient continued to slowly improve and was switched back to conventional 
ventilation. His potassium began to decrease and by post-injury day 25, it was within the normal 
range. The patient did not require dialysis. The patient underwent a tracheostomy and 
percutaneously placed gastrostomy tube without difficulty. The patient was extubated without 
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problems; he was alert and interactive. Prior to discharge, he was tolerating a regular diet and 
was transferred to a rehabilitation center on post-injury day 46. 
 
 
Figure 1 – The blue line is the patient’s potassium level. The orange line is the serum creatinine. 
The blue shade box represents when the patient was on Lovenox and the orange box is when the 




In this case report, we present a complex trauma patient who was involved in a motor vehicle 
crash. The patient sustained multiple injuries including a C7 spinal cord injury, fractured 
sternum, posterior mediastinal paraspinous hematoma which extended from T1 to T4, an 
acetabular fracture, and an L5 superior endplate fracture without compromise of the spinal canal. 
In the ER, he developed neurogenic shock and required pressors. The patient’s respiratory status 
and renal function declined early during his hospital course. He was originally placed on 
enoxaparin for DVT prophylaxis but was switched to heparin because of his decreased creatinine 
clearance. The patient’s hyperkalemia persisted while his serum creatinine began to normalize. 
Heparin was discontinued and replaced with fondaparinux 2.5 mg subcutaneous. Upon this 
switch, the patient’s potassium concentration began to normalize. 
 
The implication of unfractionated heparin in this patient’s hyperkalemia is supported secondary 
to chronological association, resolution upon alteration of therapy, and the inability to inculpate 
other interventions or baseline disease. Additionally, the persistent elevation of potassium in 
spite of repeated potassium-lowering interventions (i.e., insulin, albuterol, and furosemide) and 
the lowering of potassium in tube feedings add merit to this claim. A Naranjo Algorithm Adverse 
Drug Reaction Probability Score was tabulated at 6, which indicates the reaction was probable.5 
The only limitations to determine definite causality include failure to reintroduce the agent to the 
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patient and a lack of monitoring serum drug concentrations or dosage adjustments, neither of 
which have values or recommendations suggested in the literature. 
 
The appearance of hyperkalemia in our case implicates heparin as the inciting agent, as a 
significant increase in serum potassium occurred approximately four to seven days after its 
introduction, which is similar to that reported in the literature.6-8 Furthermore, the effect of acute 
kidney injury on our patient’s degree of hyperkalemia is contradicted by the patient’s 
improvements in serum creatinine over the same time frame (Figure 1).  
 
Aldosterone synthesis is selectively reduced in patients treated with heparin, which may be 
associated with reduced number and affinity of adrenal angiotensin II receptors in the zona 
glomerulosa, which has been suggested to occur in as many as 7% of patients.6 Previous reports 
indicate that multiple factors are typically present that exacerbate the relative aldosterone 
deficiency and alter the ability of the host to compensate. This deficiency results in the reduced 
secretion of potassium into the lumen of the late distal tubule and collecting duct with 
subsequent hyperkalemia. 
 
We switched the patient from enoxaparin to heparin as the patient’s renal function began to 
deteriorate. The dosing of enoxaparin in patients with renal dysfunction is complex. A formula 
based on the patient’s body weight, sex, and serum creatinine has been developed.9 We thought 
the simpler approach would be to switch the patient to heparin which has been used safely in 
trauma patients for decades. Also, we were uncertain when the patient’s renal function would 
stabilize. If we continued using enoxaparin, we would have been continually adjusting the 
patient’s dosing based on imprecise fluctuations in serum creatinine or repeated anti-Xa 
concentrations.  
 
One must consider other possibilities for the patient’s hyperkalemia. It is possible that this 
patient developed a contrast nephropathy. Those typically occur 24-48 hours after exposure to 
contrast dye.10 On arrival, as part of his trauma workup, this patient was exposed to contrast for 
multiple CT scans, but for the next several days, after those scans, the patient’s creatinine 
actually decreased. The patient received 100ml of Isovue 370 on the day of admission as his only 
dose of intravenous contrast. The patient’s creatinine was 1.4 mg/dL (0.70 – 1.40 mg/dl) on 
admission. During the time in question, when the patient’s creatinine begins to rise, the patient 
was not exposed to intravenous contrast dye within the previous 24-48 hours. This would 
eliminate the contrast dye as a possible cause of the patient’s hyperkalemia.  
 
Rhabdomyolysis is something else that needs to be considered. The patient had no clinical 
evidence of rhabdomyolysis. We did not obtain a creatinine kinase or a urine myoglobin while 
the patient was in the hospital. The patient had no evidence of compartment syndrome. Also, the 
patient had no evidence of adrenal dysfunction during this hospitalization. When the patient’s 
creatinine began to rise as well as his potassium, a random cortisol level was obtained. It was 
24.5 mcg/dL (3.1 – 22.4 mcg/dl). This patient did not have persistent metabolic acidosis. The 
patient’s past medical history of hypertension and diabetes predisposes him to renal dysfunction. 
This may have played a role in the patient’s acute kidney injury as well as his hyperkalemia. The 
most likely cause of the patient’s hyperkalemia is secondary to heparin. The timing of the rise in 
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serum potassium and the fact that his potassium levels began to fall shortly after the 
discontinuing of the heparin is highly suggestive that heparin was the causative agent. 
 
Finally, this trauma patient was hemodynamically unstable for his first six or seven days in the 
hospital. This is unusual. Most trauma patients will stabilize quickly once the source of the 
instability is found. We believe that the combination of the patient’s spinal cord injury plus his 
community-acquired pneumonia caused the patient to vasodilate. Therefore, his systemic 
vascular resistance was low. We responded with fluids and vasoconstrictors which worked well. 
The patient’s acute respiratory failure requiring APRV is confusing. The patient was somewhat 
overloaded, but diuresis didn’t promptly improve the patient’s pulmonary status. The patient was 




This case demonstrates the relevance of heparin-associated hyperkalemia and a need for the 
clinician to thoroughly consider this drug as a cause of refractory hyperkalemia in the critically 
ill patient. A prompt change to alternative agents like the factor Xa- inhibitors (i.e. fondaparinux) 
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